Serum neuron‐specific enolase is elevated as a novel indicator of diabetic retinopathy including macular oedema

Li, J.; Mi, Yan; Zhang, Y.; Xie, Min; Lü, Yan; Chen, J.

doi:10.1111/dme.12597

Cited by 20 publications

(19 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The mechanisms underlying brain injury in experimental models include: disruption of BBB; alteration of insulin transporter and decrease in insulin receptors, which are expressed in discrete neuronal populations in the CNS; reduction in the uptake of glucose into the neurons; impairment of energy metabolism; and impairment of the capacity of the brain to generate the connections vital to memory and learning (37). Other investigators reported raised concentrations of NSE in diabetic patients with and without overt neurologic complications (38). It is well-known that T1DM has long-term complications affecting cognitive functions (39).…”

Section: Discussionmentioning

confidence: 95%

Serum Neuron-specific Enolase and S100 Calcium-binding Protein B in Pediatric Diabetic Ketoacidosis

Elshorbagy

Barseem

Elsadek

et al. 2019

Jcrpe

View full text Add to dashboard Cite

Objective:Neuron-specific enolase (NSE) and S100 calcium-binding protein B (S100B) are markers of different neurological disorders. The aim was to investigate the relationship between NSE and S100B serum concentrations and the severity of diabetic ketoacidosis (DKA) in diabetic children.Methods:Eighty children with DKA, 40 with type 1 diabetes mellitus (T1DM) without DKA and 40 healthy controls were enrolled. Severity of DKA was assessed according to blood pH and bicarbonate concentration. Serum NSE and S100B were measured in all participants. In the DKA group serum NSE and S100B were measured at three time points, at admission and at 12 hours and 24 hours after starting treatment.Results:Children with DKA showed significantly higher serum levels of NSE at all time points compared to children with T1DM without DKA and controls (p<0.01), while serum S100B concentrations did not differ between the three cohorts. Children with T1DM but without DKA also had significantly higher serum levels of NSE (p<0.01) compared to healthy controls. Patients with low Glasgow Coma Scale score (GCSS) and those with moderate and severe DKA had significantly higher levels of NSE at all time points (p<0.01 for each) compared to patients with normal GCSS and those with mild DKA. No significant differences were found in serum S100B levels according to the severity of DKA and GCS (p>0.05). Younger age, lower GCSS, higher glucose and HbA1c, lower pH and lower serum bicarbonate were the risk factors associated with elevated NSE.Conclusion:Serum NSE is elevated in all patients with type 1 DM and, in patients with DKA, correlates with severity of DKA. However, serum S100B concentration did not differ between T1DM with or without DKA and healthy controls.

show abstract

Section: Discussionmentioning

confidence: 95%

Serum Neuron-specific Enolase and S100 Calcium-binding Protein B in Pediatric Diabetic Ketoacidosis

Elshorbagy

Barseem

Elsadek

et al. 2019

Jcrpe

View full text Add to dashboard Cite

show abstract

“…Consequently, several pathologies with distinct etiologies reported disturbed expression and/or activity of this enzyme. For instance, altered levels of ENO-1 has been demonstrated in Alzheimer’s disease (Castegna et al, 2002; Butterfield and Lange, 2009; Owen et al, 2009), rheumatoid arthritis (Kinloch et al, 2005; Montes et al, 2011), systemic sclerosis (Terrier et al, 2010; Mehra et al, 2013), type 2 diabetes (Li et al, 2013, 2015), systemic lupus erythematosus (Hawro et al, 2015; Li et al, 2018), hepatic fibrosis (Peng et al, 2013; Zhang et al, 2013), and fungal and bacterial infections (Bergmann et al, 2013; Funk et al, 2016; Ji et al, 2016). In addition, ENO-1 has been found to be overexpressed in more than 20 types of human cancer (Altenberg and Greulich, 2004).…”

Section: Introductionmentioning

confidence: 99%

When Place Matters: Shuttling of Enolase-1 Across Cellular Compartments

Didiášová

Schaefer

Wygrecka

2019

Front. Cell Dev. Biol.

108

View full text Add to dashboard Cite

Enolase is a glycolytic enzyme, which catalyzes the inter-conversion of 2-phosphoglycerate to phosphoenolpyruvate. Altered expression of this enzyme is frequently observed in cancer and accounts for the Warburg effect, an adaptive response of tumor cells to hypoxia. In addition to its catalytic function, ENO-1 exhibits other activities, which strongly depend on its cellular and extracellular localization. For example, the association of ENO-1 with mitochondria membrane was found to be important for the stability of the mitochondrial membrane, and ENO-1 sequestration on the cell surface was crucial for plasmin-mediated pericellular proteolysis. The latter activity of ENO-1 enables many pathogens but also immune and cancer cells to invade the tissue, leading further to infection, inflammation or metastasis formation. The ability of ENO-1 to conduct so many diverse processes is reflected by its contribution to a high number of pathologies, including type 2 diabetes, cardiovascular hypertrophy, fungal and bacterial infections, cancer, systemic lupus erythematosus, hepatic fibrosis, Alzheimer’s disease, rheumatoid arthritis, and systemic sclerosis. These unexpected non-catalytic functions of ENO-1 and their contributions to diseases are the subjects of this review.

show abstract

“…Neuron-specific enolase (NSE), a glycolytic enzyme, is located in the neurons and neuroendocrine cells, its physiological role is to regulate the growth and development of nerve cells. 4 Interestingly, researchers found high levels of NSE in the serum of DR patients, and the levels of NSE were closely related to the severity of DR. 5 Consistent with this, Asadova and his colleagues reported that compared with the control group, NSE was significantly increased in the serum and vitreous of patients with proliferative diabetic retinopathy (PDR). 6 However, the cause of elevated serum NSE levels in DR patients remains unknown.…”

Section: Introductionmentioning

confidence: 63%

<p>High Serum Neuron-Specific Enolase Level Is Associated with Mild Cognitive Impairment in Patients with Diabetic Retinopathy</p>

Yu¹,

Liu²,

Li³

et al. 2020

DMSO

View full text Add to dashboard Cite

Diabetic retinopathy (DR) can increase the risk of mild cognitive impairment (MCI), which has been confirmed by previous researches. With the frequent occurrence of MCI in patients with DR, the early detection of MCI has become a research hot-spot. The aim of this study was to investigate the relationship between neuron-specific enolase (NSE) and MCI in patients with DR. Patients and Methods: A total of 124 patients with DR, including 56 MCI patients and 68 normal cognition patients, were recruited in this cross-sectional study. The demographic and clinical data of patients were collected through questionnaires. Serum NSE was measured using electrochemiluminescence immunoassay. The Minimum Mental State Examination (MMSE) scale was used to evaluate the cognitive function of the participants. Results: Compared with the normal cognition group, serum NSE levels and HbA1c levels in the MCI group were higher, while MMSE scores and educational level were lower (P<0.05). Serum NSE levels were significantly negatively correlated with MMSE total score, attention and calculation score, and language score (P<0.05). After adjusting for confounding factors, serum NSE still increased the MCI risk in DR patients (OR:1.606, 95CI%:1.264-2.041, P<0.001). The areas under the receiver operating characteristics (ROC) curves (AUC) of the crude model and the adjusted model were 0.75 and 0.73, respectively. Conclusion: A high serum NSE level is an independent risk factor for MCI in DR patients. In addition, serum NSE is expected to be a potential biomarker in DR patients with MCI.

show abstract

Serum neuron‐specific enolase is elevated as a novel indicator of diabetic retinopathy including macular oedema

Abstract: Serum neuron-specific enolase is elevated in and indicative of diabetic retinopathy. Neuron-specific enolase may be a potential biomarker of diabetic retinopathy. Future prospective studies are warranted to clarify the relationship.

Cited by 20 publications

References 22 publications

Serum Neuron-specific Enolase and S100 Calcium-binding Protein B in Pediatric Diabetic Ketoacidosis

Serum Neuron-specific Enolase and S100 Calcium-binding Protein B in Pediatric Diabetic Ketoacidosis

When Place Matters: Shuttling of Enolase-1 Across Cellular Compartments

<p>High Serum Neuron-Specific Enolase Level Is Associated with Mild Cognitive Impairment in Patients with Diabetic Retinopathy</p>

Contact Info

Product

Resources

About